Floatz logo

Iparomlimab

Bevacizumab

Nanfang Hospital, Southern Medical UniversityPhase 4 / ApprovedActive
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
81/ 100

Competitive context

10 Active assets in the Bevacizumab cohort.

Asset / SponsorPhaseRating
Calcium folinate pentahydrate
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2B
Irinotecan
Nanfang Hospital, Southern Medical University
Phase 2B
(+)-VINCRISTINE
Nanfang Hospital, Southern Medical University
Phase 2B
Carboplatin
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2CCC
ETOPOSIDE
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2CCC

View all 10 →

Same molecule, other indications

Iparomlimab is also rated in:

HCC - Hepatocellular CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
ES-SCLCDormant
BB
Indicative ·
70 / 100
View asset →
CTLA-4Dormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →